We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. I took over for Danny this episode to sit down with Carter Dredge, Executive Director of the Intermountain Health Institute, to talk about Civica Rx and some of the other unique models that Dredge and his team are working on at Intermountain Health Institute! We kick this episode off by discussing why Intermountain decided to get into the pharma and life sciences business. Then we talk about what makes Civica Rx different from the traditional life sciences companies. Next, we take a look at finances to see what some of the economic dynamics are at play with Civica Rx. Dredge then shares with us some examples of the impact of this work. Then Dredge walks us through what life sciences should understand about Civica’s efforts.
We’ve heard rumors that Intermountain is starting something big in the healthcare innovation space – so we ask Dredge to give us a little teaser of what that is, its purpose, and when we should be expecting it. Then we dig into Dredge’s use of the phrase ‘healthcare utility’ to learn more about what that is and how it will influence the future of healthcare. Finally, we conclude this episode with Dredge sharing more about the publications he’s done with Cambridge Judge Business School, Professor Stefan Scholtes.
Here’s a list of some of the publications mentioned:
- Changing the Script on Drug Pricing
- Disruptive Collaboration
- The Health Care Utility Model (HCU)
- Vaccinating Health Care Supply Chains Aginst Market Failure
Check out the main topics of discussion for this episode of the Life Sciences Today podcast:
- Why did Intermountain decide to get into the pharma and life sciences business?
- What makes Civica Rx different than a traditional life sciences company?
- What are the economic dynamics at play with Civica Rx?
- Can you give us some examples of the impact of this work?
- What should life sciences understand about Civica’s efforts?
- I hear you are starting something big in the healthcare innovation space. Can you give us a little teaser of what that is, and its purpose and timeline?
- You’ve often used the phrase ‘Healthcare Utility’. Can you tell us a little more about what that is and how it will influence the future of healthcare?
- Tell us more about your publications that you’ve done with Cambridge Judge Business School, Professor Stefan Scholtes.
Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.
Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:
Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube. Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn.
If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes.
Thanks so much for listening!
No comments:
Post a Comment